Novel, Potent Inhibitors of Human Kv1.5 K+ Channels and Ultrarapidly Activating Delayed Rectifier Potassium Current
Open Access
- 1 June 2006
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 317 (3) , 1054-1063
- https://doi.org/10.1124/jpet.106.101162
Abstract
We have identified a series of diphenyl phosphine oxide (DPO) compounds that are potent frequency-dependent inhibitors of cloned human Kv1.5 (hKv1.5) channels. DPO inhibited hKv1.5 expressed in Chinese hamster ovary cells in a concentration-dependent manner preferentially during channel activation and slowed the deactivating tail current, consistent with a predominant open-channel blocking mechanism. Varying kinetics of DPO interaction with Kv1.5 channels resulted in differing potencies and frequency dependencies of inhibition that were comparable for both expressed hKv1.5 current and native ultrarapidly activating delayed rectifier potassium current (IKur) in human atrial myocytes. Selectivity of DPO versus other cardiac K+ channels was demonstrated in human atrial myocytes (IKur versus transient outward potassium current) and guinea pig ventricular myocytes [IKur versus rapidly activating delayed rectifier potassium current (IKr), slowly activating delayed rectifier potassium current (IKs) and inward rectifier potassium current (IK1), and one compound (DPO-1) was shown to be 15-fold more selective for Kv1.5 versus Kv3.1 channels expressed in Xenopus oocytes. DPO-1 also prolonged action potentials of isolated human atrial but not ventricular myocytes, in contrast to the effect of a selective IKr blocker. The selectivity and kinetics of inhibition hKv1.5 and IKur by DPO and the resulting selective prolongation of atrial repolarization could provide an effective profile for treatment of supraventricular arrhythmias.This publication has 33 references indexed in Scilit:
- The Mechanism of Atrial Antiarrhythmic Action of RSD1235Journal of Cardiovascular Electrophysiology, 2005
- “Early” Class III Drugs for the Treatment of Atrial FibrillationCirculation, 2004
- Advances in antiarrhythmic drug treatment of atrial fibrillation: where do we stand now?Heart Rhythm, 2004
- Antiarrhythmic drugs in atrial fibrillation: an overview of new agents, their mechanisms of action and potential clinical utilityExpert Opinion on Investigational Drugs, 2004
- Dronedarone: an amiodarone analogueExpert Opinion on Investigational Drugs, 2004
- Kv1.5 Is an Important Component of Repolarizing K + Current in Canine Atrial MyocytesCirculation Research, 2003
- Blockers of the Kv1.5 channel for the treatment of atrial arrhythmiasExpert Opinion on Therapeutic Patents, 2002
- Molecular Basis of Downregulation of G-Protein–Coupled Inward Rectifying K+Current (IK,ACh) in Chronic Human Atrial FibrillationCirculation, 2001
- Characterization of a novel Kv1.5 channel blocker in Xenopus oocytes, CHO cells, human and rat cardiomyocytesNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 2001
- Differences between outward currents of human atrial and subepicardial ventricular myocytes.The Journal of Physiology, 1996